Assessment of the efficacy of hydrogel-based wound dressing containing allantoin and silver nanoparticles in the treatment of second-degree burn wounds: A randomized clinical trial

开始日期2022-04-20

申办/合作机构

Mashhad University of Medical Sciences

NCT04101890

/ Terminated临床4期IIT

The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis

Diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. The incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the US. It is caused by skin exposure to a combination of several factors including: excessive moisture, topical irritants, reduced pH, friction, maceration and bacterial infection. When infants soil their diaper, diaper contents saturate the area raising the pH of the skin above the normal level of 5 or less, and leaving the area highly vulnerable to maceration from friction. Irritants in urine and feces are then able to penetrate the macerated skin, causing inflammation and greater skin friability. An elevation in the skin pH allows pathogenic bacteria to overgrow, and combined with the breakdown in the skin's outer epithelial barrier, can lead to bacterial infection. Theraworx Foam Formulation-Allantoin Liquid by Avadim Technologies, Inc. is a skin protectant with use for temporary protection of minor cuts, scrapes, burns and chapped or cracked skin. As such, Theraworx Foam used in the diaper area may be beneficial for protecting skin against diaper rash wounds, as well as for assisting with wound healing and reducing any associated pain. The purpose of this study is to determine caregivers' perceptions of the benefits of using Theraworx Foam on their infant's diaper area as part of their hygienic routine, including whether they feel the product is pleasant and easy to use, and whether they feel it helps prevent and reduce the severity of diaper dermatitis in their infants 1-14 months old.

开始日期2020-03-12

申办/合作机构

Children's National Research Institute

[+1]

100 项与尿囊素相关的临床结果

登录后查看更多信息

100 项与尿囊素相关的转化医学

登录后查看更多信息

100 项与尿囊素相关的专利（医药）

登录后查看更多信息

4,701

项与尿囊素相关的文献（医药）

2025-08-01·TALANTA

Development of a MS compatible HPLC-HILIC method for the analysis of allantoin and glycolic acid in snail slime and related dosage forms: Focus on the enantioseparation of allantoin

Article

作者: Carotti, Andrea ; Pagano, Cinzia ; Perioli, Luana ; Di Michele, Alessandro ; Bonafè, Samuele ; Protti, Michele ; Migni, Anna ; Mercolini, Laura ; Sardella, Roccaldo

Glycolic acid and allantoin are known to be responsible, at least in part, for the main activities of snail slime, such as moisturizing, skin regeneration, antioxidant, soothing and anti-inflammatory. Accordingly, a hydrophilic interaction liquid chromatography (HILIC) method for the analysis of allantoin and glycolic acid in snail slime samples was developed by a conventional UV-Vis detector and the diol-type Luna® HILIC column. An optimized eluent made up of acetonitrile/water/methanol/formic acid (90:5:5:0.1 v/v/v/v) allowed the separation of the two investigated compounds from each other and from lactic acid and hydantoin used as internal standards. Being allantoin a chiral compound, an enantioselective HPLC protocol was also developed. The chiral analysis of allantoin was performed with the Lux® 3 μm i-Amilose-3 chiral stationary phase using the same mobile phase as for the achiral analysis. The chiral method was efficiently transferred to a HPLC system coupled to triple-quadrupole mass spectrometry (MS/MS). HPLC-MS/MS analysis revealed the racemic nature of allantoin in the pure snail slime. The same profile was also observed in a prototype hydrogel prepared with snail slime. Moreover, the same method allowed to measure the amount of glycolic acid in the two investigated samples (pure snail slime and gel) and ascertain a valuable extraction recovery. The enantiomeric elution order (S)<(R) with the amylose-based phase was established coupling the results of experimental electronic circular dichroism analysis to time-dependent density functional theory simulations.

2025-08-01·AGRICULTURE ECOSYSTEMS & ENVIRONMENT

Feeding salicylates containing willow leaves to cattle modulates urea metabolism and mitigates urine-derived ammonia and nitrous oxide emissions from soil

作者: Dawid, Corinna ; Kuhla, Bjoern ; Wrage-Moennig, Nicole ; Goers, Solvig ; Mittermeier-Klessinger, Verena K. ; Mueller-Kiedrowski, Carolin B. M.

Ruminants on grazing lands have a great impact on ammonia (NH3) and nitrous oxide (N2O) emissions released from livestock productionWillow leaves are an established supplement in ruminant nutrition and are rich in salicylates and tannins, which may have a mitigating effect on NH₃ and N₂O emissions.We hypothesised that willow leaf supplementation in cattle nutrition affects nitrogen (N) and urea metabolism and mitigates urinary NH₃ and N₂O emissions from soil.Eight weaned Holstein bull calves were kept on pasture and supplemented with willow leaves or alfalfa hay in a crossover design.In a respiration chamber, feed intake, faeces and urine excretions were recorded and analyzed for total N and N-metabolites.Urea-N recycling was measured by the i.v. administration of a 13C urea tracer and a series of blood sampling.Cattle urine and artificial mimics supplemented with different salicylates were incubated with standard soil to measure NH₃ and N₂O and the N and O isotopic signatures.Despite a decline in urea turnover and N digestibility in rations supplemented with willow leaves, the leaves had no effect on microbial protein synthesis or the growth rate.Urine excretions with reduced urea but increased hippuric acid, phenolic acids, and salicylate concentrations in cattle fed willow leaves mainly inhibited bacterial denitrification processes involved in N₂O release from soil and mitigated NH₃ and N₂O emissions by 14 and 81%, resp.The results highlight intrinsic and extrinsic mechanisms that define both the nutritional significance and emission mitigation potential of supplementing cattle in pastures with willow leaves.

2025-06-01·JOURNAL OF HAZARDOUS MATERIALS

A novel framework for industrial pesticide effluent assessment: Integrating chemical screening, multi-endpoint responses and literature-based validation

Article

作者: Jin, Xiaowei ; Ji, Guixiang ; Luo, Yiwen ; Zhang, Xinyu ; Fan, Yue ; Gu, Jie ; Liang, Mengyuan

Industrial pesticide effluents pose substantial risks to aquatic ecosystems, yet comprehensive understanding of their toxicological impacts remains limited. This study presents an integrated approach to evaluate the ecological risks of pesticide manufacturing effluents through chemical screening and multi-endpoints biological responses. Using zebrafish embryos as a model organism, we demonstrated that effluent discharge point (EDP) sample induced 100 % mortality, while diluted samples exhibited significant developmental toxicity, cardiovascular injury, immunosuppression, and behavioral alterations. Non-targeted metabolomics analysis revealed the molecular mechanisms underlying these toxic responses. Through chemical screening and targeted quantification, we identified three predominant azole fungicides - propiconazole (2.11 μg/L), hexaconazole (13.3 μg/L), and tebuconazole (18.66 μg/L) - that exhibited synergistic toxicity. Notably, our innovative meta-analysis framework based on literature data validated the toxicological profiles of detected compounds, providing an efficient alternative to conventional bioassays. This study establishes a comprehensive framework for assessing industrial effluent toxicity and demonstrates the value of integrating chemical analysis with biological responses for environmental risk assessment.

项与尿囊素相关的新闻（医药）

2025-05-06

·PRNewswire

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ -- Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment by Eshelman Ventures, LLC and appointment of Dr. Eshelman as a strategic advisor for Paradigm. SD-101 (Zorblisa™) is being developed as a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB) patients. Funds will be used to complete all activities to support an NDA submission in the later part of 2025. "We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa™) and to move a path forward towards registration of this therapy for patients with all EB subtypes," said Robert Ryan., Ph.D., Chief Executive Officer of Paradigm Therapeutics. "There is a tremendous need for novel whole skin surface treatment options for treating the debilitating skin effects across all patients with Epidermolysis Bullosa. The Paradigm Therapeutics team will be working passionately to provide patients with a new therapeutic alternative in this disease with limited whole-body treatment options. Paradigm's goal is to provide this therapy to patients on a global basis and is working in parallel with potential partners to work towards this goal as quickly as possible." Dr. Ryan added, "Epidermolysis Bullosa is a devastating disease. We believe the clinical data show beneficial effects of the use of SD-101 across the range of EB patients, and strongly support progression towards registration. Results from the completed Phase II and Phase III trials indicate that SD-101 demonstrated a broad benefit with whole body treatment of the lesions and wounds on the entire skin surface in pediatric and adult patients across all EB patients, who have limited whole body treatment alternatives. Results also demonstrated that SD-101 has a favorable safety profile when used long term." "Eshelman Ventures is honored to invest in Paradigm Therapeutics and play a pivotal role in accelerating the development of SD-101 as a transformative treatment for Epidermolysis Bullosa," said Dr. Eshelman, founder of Eshelman Ventures. "As an investor and strategic advisor, I am deeply committed to working closely with this exceptional team as we work tirelessly to bring this innovative therapy to patients in need. The urgency of addressing the challenges faced by EB patients is what drives us; our goal is to provide an improved quality of life in this area of unmet need. Together, we will strive to revolutionize treatment options and make a meaningful impact on the lives of those affected by this debilitating disease." About Epidermolysis Bullosa (EB) Epidermolysis Bullosa is a rare, devastating genetic disorder causing very fragile skin that leads to severe skin blistering and open wounds often beginning at birth. There are no approved therapies that were developed to treat the entire skin surface of patients across all subtypes of EB patients, including wounds and lesional skin, which affects children and adults throughout their lifetimes. EB is a chronic disease, potentially disfiguring, and in some cases fatal. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. About SD-101 (Zorblisa™) SD-101 (Zorblisa™) is a topical cream that has demonstrated potential to provide improvement in treating the severe skin disruptions seen in patients across all EB subtypes. Phase II and Phase III studies were conducted in children and adults with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. A total of 217 EB patients were included in these studies. SD-101 was applied topically over the entire body daily in adults and children as young as 21 days old for a period of three months. The primary outcome measurement was assessment of target wound closure, in addition to secondary measurements including reduction in body surface area (BSA) coverage of blisters and wounds. SD-101 (Zorblisa™) was the first EB treatment to receive the FDA's Breakthrough Therapy designation. SD-101 (Zorblisa™) received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of EB. In addition to the Rare Pediatric Disease designation, SD-101 was granted Orphan Drug designation from the FDA and the European Commission (EC). Upon approval, Paradigm will be eligible to receive a Priority Review Voucher (PRV). About Paradigm Therapeutics, Inc. Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblisa™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 (Zorblisa™) is a topical cream that requires no special handling and can be stored at room temperature and has demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. Forward Looking Statement Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Paradigm disclaims any intent or obligation to update these forward-looking statements. Company Contact Dr. Robert Ryan Chief Executive Officer [email protected] (919)-274-0703 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果孤儿药突破性疗法临床2期

2025-05-06

·美通社

Paradigm宣布获得新投资

-Paradigm Therapeutics, Inc.宣布获得Eshelman Ventures, LLC投资，以支持完成SD-101（Zorblisa™）的开发——一种用于治疗所有亚型大疱性表皮松解症（EB）全皮肤表面的局部疗法首个用于治疗所有EB亚型患者全身皮肤表面伤口和病变的外用疗法资金将用于完成2025年下半年新药申请（NDA）所需全部工作及以及在美国的商业化计划南卡罗来纳州芒特普莱森特 2025年5月6日 /美通社/ -- 生物制药公司Paradigm Therapeutics, Inc.宣布获得Eshelman Ventures, LLC的1250万美元战略投资，并任命Eshelman博士为Paradigm的战略顾问。 SD-101（Zorblisa™）旨在开发成为首个针对所有大疱性表皮松解症（EB）亚型患者的全身外用治疗药物。本次融资将用于支持该药物在2025年下半年完成新药申请所需的全部工作。 Paradigm Therapeutics首席执行官Robert Ryan博士表示：“我们非常期待完成SD-101（Zorblisa™）的研发工作，并为所有EB亚型患者推进这一疗法的注册进程。当前亟需能够治疗所有大疱性表皮松解症患者皮肤损伤的创新全身皮肤表面治疗方案。 Paradigm Therapeutics将针对缺乏全身治疗选择的疾病，全力以赴为患者提供全新治疗方案。 Paradigm的目标是在全球范围内为患者提供这一疗法，并且目前正积极与潜在合作伙伴推进相关工作。” Ryan博士补充道：“大疱性表皮松解症是一种毁灭性的疾病。我们认为，现有临床数据表明SD-101对所有EB亚型患者显示出治疗获益，这为推进注册提供了有力支持。已完成II期和III期试验结果显示，SD-101在治疗成人和儿童EB患者全身皮肤表面的病变和伤口方面展现出广泛疗效，这些患者目前缺乏有效的全身治疗方案。结果还表明，长期使用SD-101具有良好的安全性。” Eshelman Ventures创始人Eshelman博士表示：“Eshelman Ventures很荣幸投资Paradigm Therapeutics，并在加速SD-101成为大疱性表皮松解症变革性疗法的过程中发挥关键作用。作为投资方和战略顾问，我将始终与这支优秀团队紧密合作，不懈努力，尽快为患者带来这一创新疗法。解决EB患者面临的挑战刻不容缓，这正是我们前行的动力；我们的目标是在这一亟待满足的医疗需求领域，改善患者的生活质量。我们将携手努力，革新治疗方案，为受这一顽疾困扰的患者的生活带来有意义的影响。” 关于大疱性表皮松解症（EB）大疱性表皮松解症是一种罕见的破坏性遗传疾病，患者皮肤极其脆弱，通常自出生起即出现严重水疱和开放性创面。目前尚无获批疗法可治疗所有EB亚型患者的全身皮肤表面，包括影响儿童和成人一生的伤口和病变皮肤。 EB是一种慢性疾病，可能导致毁容，严重时可危及生命。尽管EB存在多种基因型和临床表现，但所有患者都表现为皮肤极度脆弱这一共同特征——患者皮肤在轻微摩擦或外伤后就会出现水疱和撕裂。关于SD-101（Zorblisa™） SD-101（Zorblisa™）是一种外用乳霜，已证实具有改善所有EB亚型患者严重皮肤损伤的潜力。 II期和III期研究在患有单纯性、隐性营养不良（RDEB）或交界性EB的儿童和成人中开展。这些研究总共纳入了217名EB患者。成人和最小21天大的儿童每天全身外用SD-101，为期三个月。主要结果指标是目标伤口闭合情况的评估，此外还有次要指标，包括水泡和伤口的体表面积（BSA）覆盖范围的减少。 SD-101（Zorblisa™）是首个获得FDA突破性疗法认证的EB治疗药物。 SD-101（Zorblisa™）获得美国食品药品管理局（FDA）的罕见儿科疾病认定，适用范围覆盖EB的广泛治疗。除了罕见儿科疾病认定外，SD-101还获得了FDA和欧盟委员会（EC）的孤儿药认定。药物获批后，Paradigm将有资格获得优先审评券（PRV）。关于Paradigm Therapeutics, Inc. Paradigm Therapeutics, Inc.是一家私营临床阶段制药公司，专注于开发创新疗法，以满足罕见疾病治疗中的关键医疗需求。 Paradigm主要专注于大疱性表皮松解症（EB）的治疗。 SD-101（Zorblisa™）是其治疗大疱性表皮松解症患者皮肤效应的领先疗法，已完成II期和III期临床试验。 SSD-101（Zorblisa™）是一种外用乳霜，无需特殊处理，可常温保存，有望改善所有EB亚型患者的严重皮肤症状。前瞻性叙述除此处所载历史信息外，本新闻稿中讨论的事项均为前瞻性叙述，包含诸多风险和不确定性因素，包括：我们在产品开发、监管审批及商业化进程中对第三方的依赖；基于新技术开发候选产品固有的失败风险；临床开发投入相关的成本风险；以及其他风险。实际结果可能与预期存在重大差异。本前瞻性叙述仅代表本公司截至发稿时的判断。 Paradigm特此声明：本公司并无更新此前瞻性叙述的意图或义务。公司联系人 Robert Ryan博士首席执行官 rryan@paradigmtherapeutics.com (919)-274-0703

临床2期

2024-04-16

·蒲公英Ouryao

中检院：10个产品，按“药械”产品管理

转自：中检院编辑：水晶近日，中国食品药品检定研究院发布《2024年第一次医疗器械产品分类界定结果汇总》，建议按照药械组合产品判定程序界定管理属性的共10个产品。值得关注的是，含大麻二酚的药品被重新纳入管理范畴。上述文件也指出，本次10个建议按照药械组合产品判定的仅为初步建议，其具体管理属性的确定，需按药械组合产品属性界定相关要求确定。近日，中检院发布《2024年第一次医疗器械产品分类界定结果汇总》，值得关注的是，含大麻二酚的药品被重新纳入管理范畴。文件显示，建议按照药械组合产品判定程序界定管理属性的10个产品中，第一个就是鼻用抗过敏凝胶，该产品成分包括大麻二酚。文件表示，大麻二酚是从大麻植物中提取的纯天然成分，具有止痛抗炎的作用。不过，文件也指出，本次10个建议按照药械组合产品判定的仅为初步建议，其具体管理属性的确定，需按药械组合产品属性界定相关要求确定。公开资料显示，大麻二酚（CBD）是从大麻植物中提取的纯天然成分，具有止痛抗炎等功效。目前，国外已有大麻二酚相关产品上市，但我国目前还未有上市药品。建议按照药械组合产品判定程序界定管理属性的产品（10个）（一）鼻用抗过敏凝胶：由羟乙基纤维素、氯化钠（生理等渗氯化钠浓度为0.9%）、透明质酸、水、丙二醇、戊二醇、丁二醇、EumulginVL75（由月桂基葡糖苷、聚甘油-2二聚羟基硬脂酸酯、甘油组成的混合物）、泛醇、尿囊素、大麻二酚、植酸、氢氧化钠和水组成。产品一方面声称在鼻黏膜上形成保护膜，隔离花粉、灰尘、过敏原、污染、细菌、病毒等的刺激；另一方面，产品中所含成分①泛醇具有保湿、抗炎、刺激细胞分裂等作用；②尿囊素具有促进细胞生长，加快伤口愈合，软化角质蛋白等生理功能，还具有避光、杀菌防腐、止痛、抗氧化作用；③大麻二酚是从大麻植物中提取的纯天然成分，具有止痛抗炎的作用。用于具有典型症状的过敏性鼻炎和非过敏性鼻炎（如鼻塞、流涕和打喷嚏）的缓解和辅助治疗。（二）眼科手术用水凝胶：预装于注射器，为多聚核苷酸、缓冲盐和无菌注射用水组成的高分子聚合材料。为一次性使用无菌产品。在视网膜脱离患者行玻璃体切割术时，将产品注射入原玻璃体腔的位置；一方面，声称可以替代玻璃体维持眼球结构，支撑视网膜贴合眼底，帮助视网膜恢复；另一方面，所含的多聚核苷酸解聚后可特异性激活细胞表面受体，促进细胞因子的释放，产生抗炎性，修复受损细胞，帮助无定形细胞外基质成分和纤维状物质的产生；诱导细胞迁移，刺激成纤维细胞中的胶原蛋白合成；通过多聚核苷酸代谢的小寡核苷酸（核苷酸、核苷、碱基）和水分子在体内逐渐释放，为细胞生长提供营养物质。用于严重视网膜脱离后暂时填充眼内，以固定视网膜。（三）医用铜基敷料：由医用脱脂棉丝线、铜铁锌合金微丝（其中各组分比例按质量百分比为：Cu：87.00wt%、Fe：8.00wt%、Zn：5.00wt%）组成。无菌提供。声称一方面，通过直接贴覆于创面表面，并外敷纱布或棉垫保护伤口，将创面与外部环境隔离，保护创面避免受到外部环境的污染；同时通过医用脱脂棉丝线的亲水性和纤维表面及内部贯通的毛细微孔吸收保存渗液，避免创面被渗出液浸渍，起物理屏障作用，为非慢性创面愈合提供微环境。另一方面，声称所含的铜铁锌合金微丝具有抑菌作用，且声称铜合金微丝含铜、铁、锌三种生理微量元素，能促进创面快速愈合。用于非慢性创面（浅表性创面、手术后缝合创面、机械创伤、擦伤、Ⅰ度或浅Ⅱ度的烧烫伤创面）的护理，为创面愈合提供微环境。（四）氟化氨银防龋剂：由氟化氨银和塑料瓶组成。一方面声称氟化氨银涂抹在牙齿表面，与牙齿的主要成分羟基磷灰石反应，生成氟化钙和磷酸银，氟化钙进一步生成氟磷灰石，抵抗酸侵蚀。还声称涂抹在龋损部位，可在牙齿表面形成了几乎不溶的氟磷灰石、磷酸银，并沉淀在龋损表面，形成不溶性的保护层，减少龋损钙、磷离子流失，延缓龋损发展。另一方面氟化氨银具有抑菌作用，声称可减少唾液中变形链球菌。用于无龋或患龋人群，预防乳牙及恒牙龋齿，提高牙齿釉质耐酸蚀性，延缓龋损发展。（五）抗鼻腔过敏喷雾：由壳聚糖盐酸盐、聚氧乙烯（40）氢化蓖麻油、氨基硅油、芝麻油、丙二醇、丙三醇和纯化水组成。一方面，声称以喷雾的形式进入鼻腔，并覆盖在鼻腔黏膜上，通过物理隔离的方式来阻隔花粉、致病性微生物及其他颗粒性过敏物质进入鼻腔直接接触鼻腔黏膜。另一方面，本产品所含的芝麻油，又名麻油，在中医学上认为其性味甘、凉，具有润肠通便、解毒生肌之功效；而且据《本草纲目》上记载，麻油有润燥、解毒、止痛、消肿之功效。用于过敏性鼻炎患者、过敏性哮喘患者，通过阻隔致病性微生物及其他颗粒性过敏物质进入鼻腔，缓解因过敏性鼻炎、过敏性哮喘引发的相关症状。（六）医用油纱布：由上隔离层（PE网纱）、下隔离层（隔离膜）和内芯层组成。内芯层由无纺布浸渍油性物质（花生油、白蜂蜡、黄凡士林、硫酸钙、氧化锌、红氧化铁）制成的油润柔韧的薄片型。为一次性使用无菌产品。使用时，先用生理盐水清洗创面及周围皮肤，然后揭去PE网纱和隔离膜，将内芯层的正面覆盖创面，使之与创面贴合。再用医用纱布覆盖，或绷带缠扎并固定。声称一方面能在创面形成物理屏障，阻隔环境中尘灰污染以及虫蝇的侵害，形成保湿、保温的愈合环境，发挥油性隔离敷料的隔离作用，护理创面。另一方面，所含的氧化锌在药典二部中为收敛药，接触创面发挥收敛作用。用于体表非慢性创面（各种表浅层皮肤损伤，Ⅰ度、浅Ⅱ度烧烫伤创面，机械性皮肤损伤、擦伤、挫裂伤创面）的护理。（七）一次性使用阴道填塞吸附栓：由栓芯（脱脂纱布、脱脂棉、无纺布）、棉线和推送器（内推送器、外推送器）组成。栓芯中脱脂棉含有乳酸、柠檬酸、乳酸钠和柠檬酸钠成分。为一次性使用非无菌产品，有微生物限度要求。一方面，声称通过栓芯对妇科阴道炎症不良分泌物的吸附作用，降低阴道内致病微生物浓度，维护阴道局部清洁作用。另一方面，根据产品提供的抗菌实验报告结果显示产品具有抑菌作用。声称用于妇科阴道炎抗生素治疗后，当妇女阴道中的微生态环境通常会失衡，炎性分泌物持续较多时，吸附阴道炎症不良分泌物，防止阴道炎复发，辅助促进阴道炎的痊愈。（八）氟化泡沫：由氟化钠（1.2%～2.7%）、木糖醇、丙三醇、发泡剂、磷酸、纯化水、食品添加剂（植酸钠、茶多酚、维生素C）和食用香精组成。一方面，产品声称具有抑制细菌代谢生长的作用，能阻碍细菌在牙面上的粘附，减少牙菌斑内酸形成；另一方面，产品还声称能促进牙釉质的再矿化，口腔内有氟离子存在时，能促进磷灰石沉积在牙釉质表面，对脱钙的龋损部位起到再钙化的作用。用于预防龋齿。（九）无菌软膏伤口敷料：由凡士林、羧甲基纤维素钠、氧化锌和聚二甲基硅氧烷组成。无菌提供。一方面，声称在伤口上形成物理屏障，覆盖伤口，吸收伤口渗出液。另一方面，所含氧化锌在药典二部中为收敛药，接触创面发挥收敛作用。声称用于压疮和静脉淤滞性溃疡、浅表伤口、擦伤、一度和二度烧伤、伤口。还声称也用于皮肤病变或损伤所造成的创面和失禁性皮炎所造成的创面。（十）关节软骨修复材料：为猪源软骨细胞培养成的组织工程软骨经脱细胞工艺处理制成，由Ⅱ型胶原蛋白及糖胺聚糖（即硫酸软骨素钠）组成。声称不含活细胞。为一次性使用无菌产品。一方面声称与天然软骨细胞外基质的结构相似，在术后促进周围软骨细胞的移入与增殖，实现软骨原位再生；另一方面含有糖胺聚糖（即硫酸软骨素钠，已列入《中华人民共和国药典》第二部，类别为酸性黏多糖类），是一种常用的骨关节功能调节药物，主要用于缓解关节疼痛，改善关节活动度，防止骨关节退化等疾病。用于修复急慢性软骨损伤引发的软骨缺损。

寡核苷酸

100 项与尿囊素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00121	尿囊素	D02AX	DB11100

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
大疱性表皮松解	中国	江苏正大丰海制药有限公司	1982-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床前	中国	新疆医科大学	2024-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02670330 (CTgov)	临床3期	大疱性表皮松解	152	SD-101 (SD-101-6.0 to SD-101-6.0)	簾選鏇範餘獵夢夢艱鏇 = 網壓遞鏇築鹽願鏇襯鏇餘憲餘選簾襯醖壓鏇積 (獵夢壓觸網獵艱襯鑰廠, 壓築遞蓋蓋獵顧選廠願 ~ 餘憲廠鏇願夢製觸遞鹽) 更多	-	2019-08-02
				Placebo (Placebo to SD-101-6.0)	簾選鏇範餘獵夢夢艱鏇 = 選鹹鏇顧廠構築餘鏇積餘憲餘選簾襯醖壓鏇積 (獵夢壓觸網獵艱襯鑰廠, 憲積夢蓋範廠鹹鹽鑰淵 ~ 鏇襯築構鏇鹹壓鏇鏇蓋) 更多
NCT02384460 (ESSENCE, CTgov)	临床3期	大疱性表皮松解	169	SD-101-6.0 cream (SD-101-6.0 Cream)	壓積衊積鹽艱願窪鏇齋(壓鑰願鏇衊範觸襯廠鏇) = 構衊積膚築鏇製築窪構鑰願築選願積廠鏇觸醖 (鹹網醖製構鏇鑰蓋範淵, 25.50) 更多	-	2018-10-16
				Placebo (SD-101-0.0) cream (Placebo (SD-101-0.0) Cream)	壓積衊積鹽艱願窪鏇齋(壓鑰願鏇衊範觸襯廠鏇) = 製獵糧蓋壓簾艱鹽鹽鏇鑰願築選願積廠鏇觸醖 (鹹網醖製構鏇鑰蓋範淵, 28.59) 更多